250 related articles for article (PubMed ID: 19015565)
1. The cost-effectiveness of Vancouver's supervised injection facility.
Bayoumi AM; Zaric GS
CMAJ; 2008 Nov; 179(11):1143-51. PubMed ID: 19015565
[TBL] [Abstract][Full Text] [Related]
2. Is Vancouver Canada's supervised injection facility cost-saving?
Pinkerton SD
Addiction; 2010 Aug; 105(8):1429-36. PubMed ID: 20653622
[TBL] [Abstract][Full Text] [Related]
3. A cost-benefit and cost-effectiveness analysis of Vancouver's supervised injection facility.
Andresen MA; Boyd N
Int J Drug Policy; 2010 Jan; 21(1):70-6. PubMed ID: 19423324
[TBL] [Abstract][Full Text] [Related]
4. Potential cost-effectiveness of supervised injection facilities in Toronto and Ottawa, Canada.
Enns EA; Zaric GS; Strike CJ; Jairam JA; Kolla G; Bayoumi AM
Addiction; 2016 Mar; 111(3):475-89. PubMed ID: 26616368
[TBL] [Abstract][Full Text] [Related]
5. Estimating the cost-effectiveness of needle-syringe programs in Australia.
Kwon JA; Anderson J; Kerr CC; Thein HH; Zhang L; Iversen J; Dore GJ; Kaldor JM; Law MG; Maher L; Wilson DP
AIDS; 2012 Nov; 26(17):2201-10. PubMed ID: 22914579
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of syringe service programs, medications for opioid use disorder, and combination programs in hepatitis C harm reduction among opioid injection drug users: a public payer perspective using a decision tree.
Ijioma SC; Pontinha VM; Holdford DA; Carroll NV
J Manag Care Spec Pharm; 2021 Feb; 27(2):137-146. PubMed ID: 33506729
[No Abstract] [Full Text] [Related]
7. A cost-benefit/cost-effectiveness analysis of proposed supervised injection facilities in Ottawa, Canada.
Jozaghi E; Reid AA; Andresen MA; Juneau A
Subst Abuse Treat Prev Policy; 2014 Aug; 9():31. PubMed ID: 25091704
[TBL] [Abstract][Full Text] [Related]
8. Vancouver's supervised injection facility challenges Canada's drug laws.
Dooling K; Rachlis M
CMAJ; 2010 Sep; 182(13):1440-4. PubMed ID: 20805208
[No Abstract] [Full Text] [Related]
9. Health outcomes and cost-effectiveness of diversion programs for low-level drug offenders: A model-based analysis.
Bernard CL; Rao IJ; Robison KK; Brandeau ML
PLoS Med; 2020 Oct; 17(10):e1003239. PubMed ID: 33048929
[TBL] [Abstract][Full Text] [Related]
10. The projected costs and benefits of a supervised injection facility in Seattle, WA, USA.
Hood JE; Behrends CN; Irwin A; Schackman BR; Chan D; Hartfield K; Hess J; Banta-Green C; Whiteside L; Finegood B; Duchin J
Int J Drug Policy; 2019 May; 67():9-18. PubMed ID: 30802842
[TBL] [Abstract][Full Text] [Related]
11. Evaluating Vancouver's supervised injection facility: data and dollars, symbols and ethics.
Des Jarlais DC; Arasteh K; Hagan H
CMAJ; 2008 Nov; 179(11):1105-6. PubMed ID: 19015552
[No Abstract] [Full Text] [Related]
12. A cost-benefit/cost-effectiveness analysis of proposed supervised injection facilities in Montreal, Canada.
Jozaghi E; Reid AA; Andresen MA
Subst Abuse Treat Prev Policy; 2013 Jul; 8():25. PubMed ID: 23837814
[TBL] [Abstract][Full Text] [Related]
13. Mitigating the heroin crisis in Baltimore, MD, USA: a cost-benefit analysis of a hypothetical supervised injection facility.
Irwin A; Jozaghi E; Weir BW; Allen ST; Lindsay A; Sherman SG
Harm Reduct J; 2017 May; 14(1):29. PubMed ID: 28532488
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of scaling-up HCV prevention and treatment in the United States for people who inject drugs.
Barbosa C; Fraser H; Hoerger TJ; Leib A; Havens JR; Young A; Kral A; Page K; Evans J; Zibbell J; Hariri S; Vellozzi C; Nerlander L; Ward JW; Vickerman P
Addiction; 2019 Dec; 114(12):2267-2278. PubMed ID: 31307116
[TBL] [Abstract][Full Text] [Related]
15. [Needle exchange programs are a cost-effective preventative measure against HIV in Iceland].
Eythórsson ES; Ásgeirsdóttir TL; Gottfređsson M
Laeknabladid; 2014 Jul; 100(7-8):379-83. PubMed ID: 25125435
[TBL] [Abstract][Full Text] [Related]
16. Effectiveness and cost effectiveness of expanding harm reduction and antiretroviral therapy in a mixed HIV epidemic: a modeling analysis for Ukraine.
Alistar SS; Owens DK; Brandeau ML
PLoS Med; 2011 Mar; 8(3):e1000423. PubMed ID: 21390264
[TBL] [Abstract][Full Text] [Related]
17. Detachable low dead space syringes for the prevention of hepatitis C among people who inject drugs in Bristol, UK: an economic evaluation.
Hancock E; Ward Z; Ayres R; Neale J; Hussey D; Kesten JM; Hickman M; Vickerman P
Addiction; 2020 Apr; 115(4):702-713. PubMed ID: 31633849
[TBL] [Abstract][Full Text] [Related]
18. Needle exchange programs: an economic evaluation of a local experience.
Gold M; Gafni A; Nelligan P; Millson P
CMAJ; 1997 Aug; 157(3):255-62. PubMed ID: 9269195
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of integrating buprenorphine-naloxone treatment for opioid use disorder into clinical care for persons with HIV/hepatitis C co-infection who inject opioids.
Barocas JA; Morgan JR; Fiellin DA; Schackman BR; Eftekhari Yazdi G; Stein MD; Freedberg KA; Linas BP
Int J Drug Policy; 2019 Oct; 72():160-168. PubMed ID: 31085063
[TBL] [Abstract][Full Text] [Related]
20. Vancouver's supervised injection facility granted constitutional exemption from federal drug law.
HIV AIDS Policy Law Rev; 2008 Dec; 13(2-3):28-9. PubMed ID: 19294788
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
